GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » EV-to-Revenue

AbbVie (AbbVie) EV-to-Revenue

: 6.22 (As of Today)
View and export this data going back to 2012. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, AbbVie's enterprise value is $338,124 Mil. AbbVie's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $54,318 Mil. Therefore, AbbVie's EV-to-Revenue for today is 6.22.

The historical rank and industry rank for AbbVie's EV-to-Revenue or its related term are showing as below:

ABBV' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.88   Med: 5.34   Max: 7.99
Current: 6.22

During the past 13 years, the highest EV-to-Revenue of AbbVie was 7.99. The lowest was 3.88. And the median was 5.34.

ABBV's EV-to-Revenue is ranked worse than
81.95% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.31 vs ABBV: 6.22

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-20), AbbVie's stock price is $166.41. AbbVie's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $30.63. Therefore, AbbVie's PS Ratio for today is 5.43.


AbbVie EV-to-Revenue Historical Data

The historical data trend for AbbVie's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.74 5.82 5.45 5.86 5.90

AbbVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.86 5.93 5.18 5.63 5.90

Competitive Comparison

For the Drug Manufacturers - General subindustry, AbbVie's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, AbbVie's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where AbbVie's EV-to-Revenue falls into.



AbbVie EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

AbbVie's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=338123.732/54318
=6.22

AbbVie's current Enterprise Value is $338,124 Mil.
AbbVie's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $54,318 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbbVie  (NYSE:ABBV) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

AbbVie's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=166.41/30.628
=5.43

AbbVie's share price for today is $166.41.
AbbVie's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.63.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbbVie EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of AbbVie's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (AbbVie) Business Description

Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch officer: Chief Strategy Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092

AbbVie (AbbVie) Headlines

From GuruFocus

Q1 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc will Acquire ImmunoGen Inc M&A Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024